Report of the workshop on the use of chemoprophylaxis in the control of leprosy held in Amsterdam, The Netherlands on 14 December 2006.
In recent years a number of field trials have been carried out to assess the efficacy of rifampicin chemoprophylaxis for the prevention of leprosy in contacts of leprosy patients. Results from these trials are now being analysed and published. The aim of this one-day workshop was to review current evidence and discuss potential future courses of action with regard to the use of chemoprophylaxis to prevent leprosy. During the morning session the current evidence for the contribution that chemoprophylaxis may make to leprosy prevention was presented, both the results from trials (abstracts in section 1) and the outcome of modelling (abstract in section 2); in addition presentations were given on different aspects of the use of antibiotics for chemoprophylaxis (abstracts in section 3). The afternoon was devoted to discussions, a summary of which is presented in section 4 of this report. The conclusions and recommendations are given in section 5.
Oskam
L
L
KIT (Royal Tropical Institute), KIT Biomedical Research, Amsterdam, The Netherlands. l.oskam@kit.nl
Mi
Bakker
B
D018890:Chemoprevention; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000517:prevention & control*